Owning The Disease II: Adapting Strategy Into Successful Business Tactics
Owning the Disease represents a powerful new business model for medical technology companies as they seek to adapt to health care reform and a changing environment. Organizations that successfully own a disease align their incentives with those of other stakeholders in the market by developing the capabilities to deliver compelling new value propositions.
You may also be interested in...
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-two guidance documents have been posted on the tracker since its last update.